Synaptrix
Private Company
Total funding raised: $4.5M
Overview
Synaptrix Labs is an early-stage biotech company pioneering next-generation, non-invasive brain-computer interfaces (BCIs) powered by proprietary AI. Its initial focus is on assistive technology, with the Neuralis system aiming to restore mobility for paralyzed individuals through thought-controlled wheelchairs. The company is also developing a broader AI platform, NeuroDiffusion, for EEG/EMG signal processing and is exploring other applications like EMG-to-text communication. Currently in the clinical trial recruitment phase for Neuralis, Synaptrix has gained recognition through various startup competitions and accelerator programs like Nvidia Inception.
Technology Platform
Proprietary AI-based EEG/EMG signal processing platform, featuring the NeuroDiffusion™ de-noising API, designed to enable high-performance non-invasive brain-computer interfaces.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Synaptrix operates in the competitive neurotech and BCI space, facing rivals like Synchron and Paradromics (invasive BCIs) as well as other non-invasive companies such as NextMind (acquired by Snap) and open-source projects like OpenBCI. Its differentiation hinges on the claimed superior performance of its AI-driven, non-invasive signal processing platform.